VeraLight, Inc.
15
0
0
11
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
13.3%
2 terminated/withdrawn out of 15 trials
84.6%
-1.9% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 11 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
Customer Support Response Study
Role: lead
Bias Source of Signal in SCOUT DS
Role: lead
Point of Service Diabetes Screening Evaluation
Role: lead
Evaluation and Comparison of Noninvasive Blood Glucose Concentrations
Role: lead
Evaluation of Low Source of Signal in SCOUT DS
Role: lead
Evaluation of SCOUT DS in Subjects With Type 2 Diabetes #2
Role: lead
Evaluation of SCOUT DS Device in the Diagnosis of Diabetes Mellitus
Role: lead
Noninvasive Screening for Early Evidence of Diabetes With SCOUT DS
Role: lead
Screening for Early Evidence of Diabetes
Role: lead
Evaluation of a Noninvasive Diabetes Screening Device in Subjects at Risk for Diabetes
Role: lead
Evaluation of SCOUT DS in Subjects With Type 2 Diabetes
Role: lead
Evaluation of SCOUT DS Device in the Diagnosis of Diabetes
Role: lead
A Study Comparing Skin Fluorescence to Coronary Artery Calcification
Role: lead
Using SCOUT Noninvasive AGE Measurements to Forecast Diabetes Complications
Role: lead
Noninvasive Skin Spectroscopy for Diabetes Screening
Role: collaborator
All 15 trials loaded